Cargando…
Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963266/ http://dx.doi.org/10.1186/1475-2875-9-S2-P26 |
| _version_ | 1782189257335504896 |
|---|---|
| author | Noor, Ramadhani A Thiesen, Michael Mordmuller, Benjamin Milligan, Paul Atuguba, Frank Sirima, Sodiomon Issifou, Saadou Bojang, Kalifa Kironde, Fred Tiono, Alfred Okech, Brenda Chilengi, Roma Ngoa, Ateba Mukasa, Kaddu Jepsen, Soren |
| author_facet | Noor, Ramadhani A Thiesen, Michael Mordmuller, Benjamin Milligan, Paul Atuguba, Frank Sirima, Sodiomon Issifou, Saadou Bojang, Kalifa Kironde, Fred Tiono, Alfred Okech, Brenda Chilengi, Roma Ngoa, Ateba Mukasa, Kaddu Jepsen, Soren |
| author_sort | Noor, Ramadhani A |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2963266 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-29632662010-10-26 Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months Noor, Ramadhani A Thiesen, Michael Mordmuller, Benjamin Milligan, Paul Atuguba, Frank Sirima, Sodiomon Issifou, Saadou Bojang, Kalifa Kironde, Fred Tiono, Alfred Okech, Brenda Chilengi, Roma Ngoa, Ateba Mukasa, Kaddu Jepsen, Soren Malar J Poster Presentations BioMed Central 2010-10-20 /pmc/articles/PMC2963266/ http://dx.doi.org/10.1186/1475-2875-9-S2-P26 Text en Copyright ©2010 Noor et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentations Noor, Ramadhani A Thiesen, Michael Mordmuller, Benjamin Milligan, Paul Atuguba, Frank Sirima, Sodiomon Issifou, Saadou Bojang, Kalifa Kironde, Fred Tiono, Alfred Okech, Brenda Chilengi, Roma Ngoa, Ateba Mukasa, Kaddu Jepsen, Soren Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months |
| title | Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months |
| title_full | Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months |
| title_fullStr | Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months |
| title_full_unstemmed | Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months |
| title_short | Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months |
| title_sort | design of a phase iib, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the gmz2 candidate malaria vaccine in ugandan, ghanaian, burkinabe and gabonese children aged 12-60 months |
| topic | Poster Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963266/ http://dx.doi.org/10.1186/1475-2875-9-S2-P26 |
| work_keys_str_mv | AT noorramadhania designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT thiesenmichael designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT mordmullerbenjamin designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT milliganpaul designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT atugubafrank designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT sirimasodiomon designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT issifousaadou designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT bojangkalifa designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT kirondefred designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT tionoalfred designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT okechbrenda designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT chilengiroma designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT ngoaateba designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT mukasakaddu designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months AT jepsensoren designofaphaseiibrandomizedcontrolleddoubleblindmulticentrestudytoevaluatetheefficacysafetyandimmunogenicityofthegmz2candidatemalariavaccineinugandanghanaianburkinabeandgabonesechildrenaged1260months |